Erika Peterson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Erika Peterson has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Akrivi Manola
Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center, Boston, MA 02111, USA
1 shared publication - Bodi Zhang
Thorne Research, Inc., Summerville, SC 29483, USA
1 shared publication - Duraisamy Kempuraj
Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center, Boston, MA 02111, USA
1 shared publication - Jennifer A. Hogan
Graduate Program in Molecular Microbiology, Sackler School of Graduate Biomedical Sciences and Department of Molecular Biology and Microbiology, Tufts University, Boston, MA, 02111, USA.
1 shared publication Michael House
Division of Maternal Fetal Medicine, Tufts Medical Center, Boston, Massachusetts, USA
1 shared publicationSabrina Craigo
Division of Maternal Fetal Medicine, Tufts Medical Center, Boston, Massachusetts, USA
1 shared publication
Latest Publications
- 29 July 2010
- Published by Taylor & Francis in Hypertension in Pregnancy
- Vol. 29 (3) , 350-356
Risk Factors for Postpartum Antihypertensive Medication Requirement in Severe Preeclampsia
Objective: To determine antepartum risk factors for postpartum antihypertensive medication use in women with severe preeclampsia. Methods: A case control study was performed on patients who were diagnosed with severe preeclampsia between January 2000 and June 2004 at a single tertiary care center. Women discharged from the hospital on antihypertensive medications were compared to women discharged home on no antihypertensive medications. Demographic data, maternal medical conditions, and delivery data were abstracted from maternal charts. Risk factors were evaluated using multiple logistic regression. Results: 218 patients with severe preeclampsia were identified, of which 112 were discharged on antihypertensives. After adjusting for confounding variables, chronic hypertension was associated with an increased need for post partum antihypertensive medication (OR 7.5 (95% CI 3.0–18.1)). A dose-dependent association was seen with intrapartum hydralazine administration. High-dose hydralazine was associated with increased need for postpartum antihypertensive mediation (OR 5.74 95% CI 2.03–16.2) compared to low-dose hydralazine (OR of 2.51 95% CI 1.26–5.01). Hemolysis/Elevated liver function/low platelet (HELLP) syndrome was associated with a decreased need for antihypertensive medication (OR 0.33, 95% CI 0.13–0.82). Conclusions: Patients with chronic hypertension and patients who required intrapartum hydralazine were more likely to require antihypertensive medications at discharge.
- 29 July 2010
- Published by Taylor & Francis in Hypertension in Pregnancy
- Vol. 29 (3) , 350-356
Risk Factors for Postpartum Antihypertensive Medication Requirement in Severe Preeclampsia
Objective: To determine antepartum risk factors for postpartum antihypertensive medication use in women with severe preeclampsia. Methods: A case control study was performed on patients who were diagnosed with severe preeclampsia between January 2000 and June 2004 at a single tertiary care center. Women discharged from the hospital on antihypertensive medications were compared to women discharged home on no antihypertensive medications. Demographic data, maternal medical conditions, and delivery data were abstracted from maternal charts. Risk factors were evaluated using multiple logistic regression. Results: 218 patients with severe preeclampsia were identified, of which 112 were discharged on antihypertensives. After adjusting for confounding variables, chronic hypertension was associated with an increased need for post partum antihypertensive medication (OR 7.5 (95% CI 3.0–18.1)). A dose-dependent association was seen with intrapartum hydralazine administration. High-dose hydralazine was associated with increased need for postpartum antihypertensive mediation (OR 5.74 95% CI 2.03–16.2) compared to low-dose hydralazine (OR of 2.51 95% CI 1.26–5.01). Hemolysis/Elevated liver function/low platelet (HELLP) syndrome was associated with a decreased need for antihypertensive medication (OR 0.33, 95% CI 0.13–0.82). Conclusions: Patients with chronic hypertension and patients who required intrapartum hydralazine were more likely to require antihypertensive medications at discharge.
- Open Access
- 11 March 2010
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 7 (1) , 20
Mercury induces inflammatory mediator release from human mast cells
Background: Mercury is known to be neurotoxic, but its effects on the immune system are less well known. Mast cells are involved in allergic reactions, but also in innate and acquired immunity, as well as in inflammation. Many patients with Autism Spectrum Disorders (ASD) have "allergic" symptoms; moreover, the prevalence of ASD in patients with mastocytosis, characterized by numerous hyperactive mast cells in most tissues, is 10-fold higher than the general population suggesting mast cell involvement. We, therefore, investigated the effect of mercuric chloride (HgCl2) on human mast cell activation.Methods: Human leukemic cultured LAD2 mast cells and normal human umbilical cord blood-derived cultured mast cells (hCBMCs) were stimulated by HgCl2 (0.1-10 μM) for either 10 min for beta-hexosaminidase release or 24 hr for measuring vascular endothelial growth factor (VEGF) and IL-6 release by ELISA.Results: HgCl2induced a 2-fold increase in β-hexosaminidase release, and also significant VEGF release at 0.1 and 1 μM (311 ± 32 pg/106cells and 443 ± 143 pg/106cells, respectively) from LAD2 mast cells compared to control cells (227 ± 17 pg/106cells, n = 5, p < 0.05). Addition of HgCl2(0.1 μM) to the proinflammatory neuropeptide substance P (SP, 0.1 μM) had synergestic action in inducing VEGF from LAD2 mast cells. HgCl2also stimulated significant VEGF release (360 ± 100 pg/106cells at 1 μM, n = 5, p < 0.05) from hCBMCs compared to control cells (182 ± 57 pg/106cells), and IL-6 release (466 ± 57 pg/106cells at 0.1 μM) compared to untreated cells (13 ± 25 pg/106cells, n = 5, p < 0.05). Addition of HgCl2(0.1 μM) to SP (5 μM) further increased IL-6 release.Conclusions: HgCl2stimulates VEGF and IL-6 release from human mast cells. This phenomenon could disrupt the blood-brain-barrier and permit brain inflammation. As a result, the findings of the present study provide a biological mechanism for how low levels of mercury may contribute to ASD pathogenesis.
- 11 March 2010
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 7 (1) , 20
Open AccessMercury induces inflammatory mediator release from human mast cells
Background: Mercury is known to be neurotoxic, but its effects on the immune system are less well known. Mast cells are involved in allergic reactions, but also in innate and acquired immunity, as well as in inflammation. Many patients with Autism Spectrum Disorders (ASD) have "allergic" symptoms; moreover, the prevalence of ASD in patients with mastocytosis, characterized by numerous hyperactive mast cells in most tissues, is 10-fold higher than the general population suggesting mast cell involvement. We, therefore, investigated the effect of mercuric chloride (HgCl2) on human mast cell activation.Methods: Human leukemic cultured LAD2 mast cells and normal human umbilical cord blood-derived cultured mast cells (hCBMCs) were stimulated by HgCl2 (0.1-10 μM) for either 10 min for beta-hexosaminidase release or 24 hr for measuring vascular endothelial growth factor (VEGF) and IL-6 release by ELISA.Results: HgCl2induced a 2-fold increase in β-hexosaminidase release, and also significant VEGF release at 0.1 and 1 μM (311 ± 32 pg/106cells and 443 ± 143 pg/106cells, respectively) from LAD2 mast cells compared to control cells (227 ± 17 pg/106cells, n = 5, p < 0.05). Addition of HgCl2(0.1 μM) to the proinflammatory neuropeptide substance P (SP, 0.1 μM) had synergestic action in inducing VEGF from LAD2 mast cells. HgCl2also stimulated significant VEGF release (360 ± 100 pg/106cells at 1 μM, n = 5, p < 0.05) from hCBMCs compared to control cells (182 ± 57 pg/106cells), and IL-6 release (466 ± 57 pg/106cells at 0.1 μM) compared to untreated cells (13 ± 25 pg/106cells, n = 5, p < 0.05). Addition of HgCl2(0.1 μM) to SP (5 μM) further increased IL-6 release.Conclusions: HgCl2stimulates VEGF and IL-6 release from human mast cells. This phenomenon could disrupt the blood-brain-barrier and permit brain inflammation. As a result, the findings of the present study provide a biological mechanism for how low levels of mercury may contribute to ASD pathogenesis.